rs267607048
Variant summary
The NM_007373.4(SHOC2):c.4A>G (p.Ser2Gly) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a cumulative frequency of 0.00000342 (AC=5) in the gnomAD database across 1,460,838 control chromosomes (no homozygotes observed). The grpmax filtering allele frequency (95% CI) is 0.0000147. Note: a gnomAD entry for this variant shows a statistical allele-bias signature, consistent with mosaic/somatic contamination (e.g. age-related clonal hematopoiesis) rather than true inherited population frequency — this frequency should not be read as evidence of a common, benign germline variant. Splicing prediction tools (SpliceAI) predict no significant impact on normal splicing. The affected nucleotide is highly conserved across species (PhyloP 100-way vertebrate score: 8.49). Variant has been reported in ClinVar as Pathogenic/Likely Pathogenic (★★★). ClinVar reports functional evidence for this variant: "SCV000605107: Functional characterization of the p.Ser2Gly protein indicates enhanced myristoylation, and aberrant targeting of the SHOC2 to the cell membrane in the absence of growth factor signaling (Cordeddu 2009). PMID:19684605" and additional evidence is available in ClinVar. Other variants at the same amino acid position have been reported in ClinVar (not pathogenic): p.S2T: Uncertain_significance (ClinVar VariationId 2265459, 1 star) This exact variant is established as oncogenic in: CGI (Cancer Genome Interpreter). This exact variant is curated in the UniProt human variants database as Uncertain Significance; it is also listed as a COSMIC curated somatic variant.
Frequency
Consequence
NM_007373.4 missense
Scores
Clinical Significance
Conservation
Publications
- Noonan syndrome-like disorder with loose anagen hairInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, ClinGen
- Noonan syndrome-like disorder with loose anagen hair 1Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: PanelApp Australia, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), G2P
- cardiofaciocutaneous syndromeInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
- Costello syndromeInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
- Noonan syndromeInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
Classification according to ACMG Germline Pathogenicity v2019
Our verdict: Pathogenic. The variant received 13 points.
| Apply | Criterion Code & Title / Strength | Rationale / Clinical Context | |
|---|---|---|---|
| PS3Functional studies show damaging effect | Well-established functional study supports damaging effect (PS3); SCV000605107: Functional characterization of the p.Ser2Gly protein indicates enhanced myristoylation, and aberrant targeting of the SHOC2 to the cell membrane in the absence of growth factor signaling (Cordeddu 2009). PMID: 19684605; SCV000616382: "In vitro functional studies provide some evidence that the p.Ser2Gly variant may impact protein function (PS3; PMID: 19684605)."; SCV002012001: Functional studies provide strong evidence of the variant having a damaging effect on the gene or gene product (PMID: 19684605).; SCV002767174: Functional studies have demonstrated this variant causes impaired nuclear translocation and MAPK activation (PMID: 19684605); Missense variants in this gene result in enhanced MAPK activation (OMIM, PMID: 19684605).; SCV004171888: Functional studies indicate that this variant has a damaging effect on the gene or the gene product (Cordeddu V, et. al., 2009).; SCV005685488: "In vitro functional studies provide some evidence that the p.Ser2Gly variant may impact protein function." PMID:19684605; SCV000253914: Experimental studies have shown that this missense change affects SHOC2 function (PMID: 19684605, 22606262).; SCV000699328: From functional studies this variant was found to introduce an N-myristoylation site, resulting in aberrant targeting of SHOC2 to the plasma membrane and impaired translocation to the nucleus upon growth factor stimulation. Expression of SHOC2-S2G in vitro enhanced MAPK activation in a cell type specific fashion. Induction of SHOC2-S2G in Caenorhabditis elegans engendered protruding vulva, a neomorphic phenotype associated with aberrant signaling (Cordeddu_2009). In other functional study, the SHOC2-S2G mutant did not rescue ERK1/2 activation in Shoc2-depleted cells and the mutant was not located in late endosomes, however it was present on the plasma membrane and early endosomes (Galperin_2012).; SCV000062456: "In vitro functional studies provide some evidence that the p.Ser2Gly variant impacts protein function (Cordeddu 2009)."; SCV002817221: Assessment of experimental evidence suggests this variant results in abnormal protein function (PMID: 19684605, 22606262).; SCV005350870: Functional studies found that this variant results in aberrant targeting of SHOC2 protein to the plasma membrane, impaired translocation to the nucleus upon growth factor stimulation, and enhanced MAPK activation in a cell type specific manner (Cordeddu et al. 2009. PubMed ID: 19684605). | ||
| PM2Absent/extremely low in population databases | Rare in gnomAD for AD/XL gene (popmax AF below threshold) — PM2 Supporting; GnomAD popmax AF = 0.0000147 — borderline rare for AD/XL gene (threshold 0.0001) — PM2 supporting. | ||
| PP5Reputable source reports pathogenic | ClinVar ≥3 stars pathogenic — very strong (PP5); ClinVar submissions overwhelmingly pathogenic (≥10 total, ≥80% P/LP, <10% B/LB) — strong (PP5, count-based); ClinVar germline classification: Pathogenic/Likely Pathogenic, 3 star(s). ClinVar submissions strongly and reliably favor pathogenicity (50/50 total P/LP). |
Variant Effect in Transcripts
Automated classification analysis was done for transcript: NM_007373.4. You can select a different transcript below to see updated classification assignments.
RefSeq Transcripts
Ensembl Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| SHOC2 | TSL:1 MANE Select | c.4A>G | p.Ser2Gly | missense | Exon 2 of 9 | ENSP00000358464.5 | Q9UQ13-1 | ||
| SHOC2 | c.4A>G | p.Ser2Gly | missense | Exon 3 of 10 | ENSP00000510210.1 | Q9UQ13-1 | |||
| SHOC2 | c.4A>G | p.Ser2Gly | missense | Exon 2 of 9 | ENSP00000509273.1 | Q9UQ13-1 |
Frequencies
Allele frequencies (AF), counts (AC/AN), homozygotes and coverage
| Source / population | AF | AC | Hom | AN | Coverage |
|---|---|---|---|---|---|
Global population databases 4 sources | |||||
GnomAD3 genomes | AF: 0.00000657 | AC:1 | Hom:0 | AN:152166 | Cov:32 |
GnomAD4 exome | AF: 0.00000342 | AC:5 | Hom:0 | AN:1460838 | Cov:31 |
GnomAD4 genome | AF: 0.00000657 | AC:1 | Hom:0 | AN:152166 | Cov:32 |
ALFA (dbGaP/dbSNP Allele Frequency Aggregator) | AF: 0.00000979 | AC:2 | Hom:0 | AN:204292 | |
ClinVar
Computational Scores
| Algorithm | Calibrated pred. | Score | Prediction |
|---|---|---|---|
AlphaGenome AVI | Pathogenic | 21 | |
AlphaMissense | Benign | 0.11 | |
BayesDel_addAF | Uncertain | 0.16 | D |
BayesDel_noAF | Uncertain | -0.010 | |
CADD | Uncertain | 25 | |
DANN | Uncertain | 1.0 | |
DEOGEN2 | Benign | 0.17 | T |
Eigen | Uncertain | 0.51 | |
Eigen_PC | Uncertain | 0.58 | |
FATHMM_MKL | Pathogenic | 0.99 | D |
GPN-Star LLR | N/A | -7.4 | |
GPN-Star score | N/A | 7.4 | |
LIST_S2 | Benign | 0.76 | T |
M_CAP | Benign | 0.023 | T |
MetaRNN | Pathogenic | 0.85 | D |
MetaSVM | Benign | -0.87 | T |
Mutation Taster | N/A | 13/87 | disease causing (ClinVar) |
MutationAssessor | Benign | 1.9 | M |
PhyloP100 | Pathogenic | 8.5 | |
popEVE | Benign | -3.3 | |
PrimateAI | Uncertain | 0.71 | T |
PROVEAN | Benign | -0.35 | N |
REVEL | Uncertain | 0.39 | |
Sift | Pathogenic | 0.0 | D |
Sift4G | Benign | 0.60 | T |
Varity_R | N/A | 0.44 | |
VESM-3B | Benign | -4.3 |
Splicing Scores
| Algorithm | Calibrated pred. | Score | Prediction |
|---|---|---|---|
Pangolin (max) | Benign | 0.0 | |
SpliceAI score (max) | Benign | 0.0 | Details are displayed if max score is > 0.2 |
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.